Search - tctmd.com

Displaying 701 - 720 of 829

Sort: Relevancy | Date

CHANGE DAPT: Study Contests Benefit of Ticagrelor Over Clopidogrel After PCI in ACS

News Conference News ESC 2017

CHANGE DAPT: Study Contests Benefit of Ticagrelor Over Clopidogrel After PCI in ACS

August 30, 2017

Anacetrapib Finds (Modest) Success Where All Other CETP Inhibitors Failed

News Conference News ESC 2017

Anacetrapib Finds (Modest) Success Where All Other CETP Inhibitors Failed

Michael O'Riordan

August 29, 2017

News Industry News

RE-DUAL PCI™ Results Offer Favorable New Safety Data on Pradaxa®

August 28, 2017

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

News Conference News ESC 2017

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

Michael O'Riordan

August 27, 2017

COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease

News Conference News ESC 2017

COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease

August 27, 2017

Lower Blood Pressure May Protect Against Cognitive Decline in Adults in Their 70s

News Daily News

Lower Blood Pressure May Protect Against Cognitive Decline in Adults in Their 70s

August 22, 2017

ESC 2017: In Tragedy’s Wake, Cardiology’s Biggest Congress Forges On, With Hotly Anticipated Trials

News Opinion Editor's Corner ESC 2017

ESC 2017: In Tragedy’s Wake, Cardiology’s Biggest Congress Forges On

August 18, 2017

Fibrinolytic Agents for STEMI: Meta-analysis Explores the Differences

News Daily News

Fibrinolytic Agents for STEMI: Meta-analysis Explores the Differences

August 18, 2017

Money-Back Guarantee for Evolocumab Has Little Impact on Cost-Effectiveness

News Daily News

Money-Back Guarantee for Evolocumab Has Little Impact on Cost-Effectiveness

Michael O'Riordan

August 08, 2017

CKD Patients Undergoing PCI Much Less Likely to Receive Potent P2Y12 Inhibition

News Daily News

CKD Patients Undergoing PCI Much Less Likely to Receive Potent P2Y12 Inhibition

Michael O'Riordan

August 04, 2017

How SGLT2 Inhibitors Help the Heart: Biomarker Study Offers Clues

News Daily News

How SGLT2 Inhibitors Help the Heart: Biomarker Study Offers Clues

August 01, 2017

Staying on Statins After an Adverse Event Lowers Risks of Death, MI or Stroke

News Daily News

Staying on Statins After an Adverse Event Lowers Risks of Death, MI or Stroke

Michael O'Riordan

July 25, 2017

Hormone Therapies May Have Adverse CV Effects in Transgender Adults

News Daily News

Hormone Therapies May Have Adverse CV Effects in Transgender Adults

July 24, 2017

Coronary Calcium Scores in 2017: Useful, Yes, but Hard Outcomes Data Still Lacking

News Conference News SCCT 2017

Coronary Calcium Scores in 2017: Useful, Yes, but Hard Outcomes Data Still Lacking

Yael L. Maxwell

July 13, 2017

Nonobstructive Coronary Disease on Cardiac CT: Call to Action, or Wait and See?

News Conference News SCCT 2017

Nonobstructive Coronary Disease on Cardiac CT: Call to Action, or Wait and See?

Yael L. Maxwell

July 10, 2017

TCTMD’s Top 10 Most Popular Stories for June 2017

News Daily News

TCTMD’s Top 10 Most Popular Stories for June 2017

July 03, 2017

Top-Line REVEAL Results Support Efficacy of CETP Inhibition, but Questions Abound

News Daily News

Top-Line REVEAL Results Support Efficacy of CETP Inhibition, but Questions Abound

June 27, 2017

Debating the ARB/MI Paradox: Is It Real, or Is the Story Incomplete?

News Daily News

Debating the ARB/MI Paradox: Is It Real, or Is the Story Incomplete?

Michael O'Riordan

June 05, 2017

TCTMD’s Top 10 Most Popular Stories for May 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for May 2017

June 01, 2017

Therapies Aimed at New Genetic Target Show Early Promise for Lowering Triglycerides

News Daily News

Therapies Aimed at New Genetic Target Show Early Promise for Lowering Triglycerides

May 26, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.